Literature DB >> 27554755

Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development.

P Zaratin1, G Comi2, T Coetzee3, K Ramsey3, K Smith3, A Thompson4, M Panzara5.   

Abstract

The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developing treatments for progressive multiple sclerosis (MS). This innovative model promises to facilitate robust collaboration between industry, academia, and patient organizations and accelerate research towards the overarching goal of developing safe and effective treatments for progressive MS.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh：

Year:  2016        PMID： 27554755     DOI： 10.1016/j.tips.2016.07.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  7 in total

1.  Collective health research assessment: developing a tool to measure the impact of multistakeholder research initiatives.

Authors:  Anna-Aurora Kork; Carla Antonini; Nicolás García-Torea; Mercedes Luque-Vílchez; Ericka Costa; Juliette Senn; Carlos Larrinaga; Deborah Bertorello; Giampaolo Brichetto; Paola Zaratin; Michele Andreaus
Journal:  Health Res Policy Syst       Date:  2022-05-02

Review 2.  Imaging outcome measures for progressive multiple sclerosis trials.

Authors:  Marcello Moccia; Nicola de Stefano; Frederik Barkhof
Journal:  Mult Scler       Date:  2017-10       Impact factor: 6.312

3.  Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10.

Authors:  Marcello Moccia; Antonio Capacchione; Roberta Lanzillo; Fortunata Carbone; Teresa Micillo; Giuseppe Matarese; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Brain Sci       Date:  2019-09-27

4.  Fitness Shifts the Balance of BDNF and IL-6 from Inflammation to Repair among People with Progressive Multiple Sclerosis.

Authors:  Augustine Joshua Devasahayam; Liam Patrick Kelly; John Bradley Williams; Craig Stephen Moore; Michelle Ploughman
Journal:  Biomolecules       Date:  2021-03-26

Review 5.  Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.

Authors:  Alan J Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J Fox; Anne Helme; Reinhard Hohlfeld; Robert Hyde; Pamela Kanellis; Douglas Landsman; Catherine Lubetzki; Ruth Ann Marrie; Julia Morahan; Xavier Montalban; Bruno Musch; Sarah Rawlings; Marco Salvetti; Finn Sellebjerg; Caroline Sincock; Kathryn E Smith; Jon Strum; Paola Zaratin; Timothy Coetzee
Journal:  Mult Scler       Date:  2021-12-01       Impact factor: 6.312

6.  The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care.

Authors:  Paola Zaratin; Deborah Bertorello; Roberta Guglielmino; Danilo Devigili; Giampaolo Brichetto; Valentina Tageo; Gabriele Dati; Stephanie Kramer; Mario Alberto Battaglia; Monica Di Luca
Journal:  Health Res Policy Syst       Date:  2022-02-17

7.  Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance.

Authors:  Paola Zaratin; Brenda Banwell; Timothy Coetzee; Giancarlo Comi; Anthony Feinstein; Robert Hyde; Marco Salvetti; Kathryn Smith
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.